Business Description
Autolus Therapeutics PLC
NAICS : 541714
SIC : 2834
ISIN : US05280R1005
Share Class Description:
AUTL: ADRTotal Employee Number:
752Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.87 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | -0.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.02 | |||||
Beneish M-Score | 15.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 63.3 | |||||
3-Year EBITDA Growth Rate | 13.6 | |||||
3-Year EPS without NRI Growth Rate | 11.5 | |||||
3-Year FCF Growth Rate | 3.4 | |||||
3-Year Book Growth Rate | -27.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 60.41 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.66 | |||||
9-Day RSI | 43.59 | |||||
14-Day RSI | 45.51 | |||||
3-1 Month Momentum % | 0.67 | |||||
6-1 Month Momentum % | 4.17 | |||||
12-1 Month Momentum % | -39.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.8 | |||||
Quick Ratio | 5.28 | |||||
Cash Ratio | 3.61 | |||||
Days Inventory | 94.1 | |||||
Days Sales Outstanding | 98.72 | |||||
Days Payable | 18.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.4 | |||||
Shareholder Yield % | -4.48 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -11.19 | |||||
Operating Margin % | -285.91 | |||||
Net Margin % | -311.98 | |||||
EBITDA Margin % | -266.89 | |||||
FCF Margin % | -318.38 | |||||
OCF Margin % | -295.09 | |||||
ROE % | -113.77 | |||||
ROA % | -44.52 | |||||
ROIC % | -108.16 | |||||
3-Year ROIIC % | -69.9 | |||||
ROC (Joel Greenblatt) % | -191.1 | |||||
ROCE % | -44.55 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.29 | |||||
PB Ratio | 3.68 | |||||
Price-to-Tangible-Book | 4.47 | |||||
EV-to-EBIT | -0.98 | |||||
EV-to-Forward-EBIT | -0.94 | |||||
EV-to-EBITDA | -1.02 | |||||
EV-to-Revenue | 2.72 | |||||
EV-to-Forward-Revenue | 1.84 | |||||
EV-to-FCF | -0.86 | |||||
Price-to-GF-Value | 0.08 | |||||
Earnings Yield (Greenblatt) % | -102.04 | |||||
FCF Yield % | -73.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AUTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Autolus Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 92.624 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 3.0996 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 84.87 | ||
| 14-Day RSI | 45.51 | ||
| 14-Day ATR ($) | 0.112826 | ||
| 20-Day SMA ($) | 1.5785 | ||
| 12-1 Month Momentum % | -39.76 | ||
| 52-Week Range ($) | 1.175 - 2.7 | ||
| Shares Outstanding (Mil) | 266.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Autolus Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:30 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 119 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 27 days | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-30 09:00 | 1.65 (+2.48%) | ||
| General meeting for 2026 | 2026-06-29 10:00 | 1.61 (+1.26%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 10:30 | 1.75 (-3.31%) | ||
| William Blair\'s 46th Annual Growth Stock Conference | 2026-06-02 13:20 | 1.84 (-1.08%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:30 | 1.71 (+7.55%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.71 (+7.55%) |
Show
Entries
Autolus Therapeutics PLC Frequently Asked Questions
What is Autolus Therapeutics PLC(AUTL)'s stock price today?
The current price of AUTL is $1.52. The 52 week high of AUTL is $2.70 and 52 week low is $1.18.
When is next earnings date of Autolus Therapeutics PLC(AUTL)?
The next earnings date of Autolus Therapeutics PLC(AUTL) is 2026-08-12 Est..
Does Autolus Therapeutics PLC(AUTL) pay dividends? If so, how much?
Autolus Therapeutics PLC(AUTL) does not pay dividend.
Guru Commentaries on NAS:AUTL
No articles.
Press Release
Articles on Autolus Therapeutics PLC
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers